Glenmark's RYALTRIS gains FDA approval for children 6–11

The U.S. FDA expanded the indication for RYALTRIS to include children aged 6 to less than 12 with Seasonal Allergic Rhinitis, broadening its use alongside adults and older youths. The approval, supported by a Phase 3 trial of 446 children showing improved nasal symptoms and good tolerability, coincides with Glenmark’s plan to transition to direct U.S. commercialization by April 1, 2026.